Literature DB >> 3920357

Serum carbonic anhydrase III in progressive muscular dystrophy.

K Mokuno, S Riku, Y Matsuoka, I Sobue, K Kato.   

Abstract

Serum carbonic anhydrase III (CA-III) levels were determined by means of an enzyme immunoassay method and compared with serum creatine kinase (CK) and muscle-specific enolase (MSE) levels in 143 patients with four types of progressive muscular dystrophy (PMD), namely, Duchenne muscular dystrophy (DMD), limb-girdle dystrophy, facioscapulohumeral dystrophy and congenital dystrophy. Serum CA-III levels were raised in the majority of patients, especially in those with DMD. In DMD patients, the gradual decline in the CA-III level was observed with age. High correlations were found between CA-III, CK and MSE levels. The frequency of cases with elevated CA-III levels was the same as or greater than that of elevated CK or MSE levels in four types of PMD. These results suggest that serum CA-III may be a useful marker of muscle disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920357     DOI: 10.1016/0022-510x(85)90118-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Muscle carbonic anhydrase III levels in normal and muscular dystrophia afflicted chickens.

Authors:  Toshiho Nishita; Daisuke Yorifuji; Kensuke Orito; Nobutsune Ichihara; Kazuyoshi Arishima
Journal:  Acta Vet Scand       Date:  2012-05-29       Impact factor: 1.695

2.  Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.

Authors:  Burcu Ayoglu; Amina Chaouch; Hanns Lochmüller; Luisa Politano; Enrico Bertini; Pietro Spitali; Monika Hiller; Eric H Niks; Francesca Gualandi; Fredrik Pontén; Kate Bushby; Annemieke Aartsma-Rus; Elena Schwartz; Yannick Le Priol; Volker Straub; Mathias Uhlén; Sebahattin Cirak; Peter A C 't Hoen; Francesco Muntoni; Alessandra Ferlini; Jochen M Schwenk; Peter Nilsson; Cristina Al-Khalili Szigyarto
Journal:  EMBO Mol Med       Date:  2014-07       Impact factor: 12.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.